NASDAQ · XTLB
Healthcare · Biotechnology
$2.02
Down-$0.16 (-7.34%)
Updated Oct 7, 2026, 10:38 AM
SID Score
3.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · XTLB
1M range · 18 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
XTLB closed at $2.02 after 18 trading sessions, down 20.16% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $2.17 | $2.26 | $2.02 | $2.02 | 36.96K |
| Oct 5, 2026 | $2.20 | $2.355 | $2.17 | $2.18 | 12.93K |
| Oct 2, 2026 | $2.17 | $2.2126 | $2.16 | $2.16 | 6.74K |
| Oct 1, 2026 | $2.42 | $2.42 | $2.13 | $2.13 | 7.14K |
| Sep 30, 2026 | $2.325 | $2.325 | $2.30 | $2.30 | 1.56K |
| Sep 29, 2026 | $2.2643 | $2.2816 | $2.11 | $2.2099 | 24.25K |
| Sep 28, 2026 | $2.27 | $2.44 | $2.23 | $2.23 | 3.64K |
| Sep 25, 2026 | $2.30 | $2.43 | $2.2001 | $2.2001 | 1.04K |
| Sep 24, 2026 | $2.22 | $2.50 | $2.22 | $2.4101 | 13.27K |
| Sep 23, 2026 | $2.39 | $2.4043 | $2.2001 | $2.2001 | 2.54K |
| Sep 21, 2026 | $2.27 | $2.3784 | $2.1859 | $2.3784 | 750.05 |
| Sep 17, 2026 | $2.40 | $2.40 | $2.35 | $2.40 | 3K |
| Sep 16, 2026 | $2.4788 | $2.49 | $2.38 | $2.39 | 1.73K |
| Sep 15, 2026 | $2.40 | $2.4999 | $2.28 | $2.4999 | 5.34K |
| Sep 14, 2026 | $2.47 | $2.51 | $2.40 | $2.43 | 2.22K |
| Sep 11, 2026 | $2.475 | $2.559 | $2.465 | $2.559 | 1.6K |
| Sep 9, 2026 | $2.436 | $2.5602 | $2.40 | $2.52 | 6.26K |
| Sep 8, 2026 | $2.5297 | $2.53 | $2.5297 | $2.53 | 666.55 |
The latest Smart Investors Daily articles mentioning XTLB.
Company
Market Activity
Research & News
XTLB research
Company profile and research snapshot.
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Benzinga · Feb 27, 2026
According to Nasdaq staff, XTLB qualifies as a "public shell" and does not warrant continued listing of its ADS.
Yahoo · Jan 29, 2026
RAMAT GAN, ISRAEL, Jan. 29, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), announced that it is working diligently to close the acquisition of 85% of the shares of NeuroNOS Ltd. from Beyond Air Inc, following the execution of the Binding Letter of Intent on January 13 , 2026 (as disclosed in the Company’s Report of Foreign Private Issuer on Form 6-K filed on January 13, 2026), and has already scheduled a shareholders meeting for Februa
Benzinga · Jan 29, 2026
XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) (TASE:XTLB.TA) (the "Company" or "XTL"), announced that it is working diligently to close the acquisition of 85% of the shares of NeuroNOS Ltd. from Beyond Air Inc, following the
Investing.com · Jul 22, 2024
XTL Biopharmaceuticals, an Israeli pharmaceutical company, announced the results of its Annual and Extraordinary General Meeting, including the re-election of board members and the appointment of independent auditors. The company also confirmed the acquisition of The Social Proxy Ltd., which will add two new directors to its board.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning XTLB.
No results
No recent SID articles mention XTLB.
